Aggressive treatment may be needed for idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Cheng P;Cheng P; Xie Q; Xie Q; Liu S; Liu S; Liu X; Liu X; Wang L; Wang L; Hao CM; Hao CM
  • Source:
    Revista da Associacao Medica Brasileira (1992) [Rev Assoc Med Bras (1992)] 2024 May 03; Vol. 70 (4), pp. e20230871. Date of Electronic Publication: 2024 May 03 (Print Publication: 2024).
  • Publication Type:
    Journal Article; Multicenter Study
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Associação Médica Brasileira Country of Publication: Brazil NLM ID: 9308586 Publication Model: eCollection Cited Medium: Internet ISSN: 1806-9282 (Electronic) Linking ISSN: 01044230 NLM ISO Abbreviation: Rev Assoc Med Bras (1992) Subsets: MEDLINE
    • Publication Information:
      Original Publication: São Paulo : Associação Médica Brasileira
    • Subject Terms:
    • Abstract:
      Objective: The purpose of this study was to analyze the clinical, pathological, prognostic features and treatment response of the coexistence of focal segmental glomerulosclerosis lesions with idiopathic membranous nephropathy.
      Methods: This is a two-center retrospective cohort study. Patients of idiopathic membranous nephropathy were enrolled and divided into two groups with or without focal segmental glomerulosclerosis lesions according to the renal biopsy. Laboratory data and pathological manifestation were compared. Renal phospholipase A2 receptor was detected by immunofluorescence. During the follow-up, the effects of different therapies and renal function were estimated.
      Results: A total of 236 patients were finally enrolled in this study, of which 60 and 176 idiopathic membranous nephropathy patients were enrolled in the FSGS+ and FSGS- groups, respectively. The FSGS+ group showed a higher percentage of hypertension history (38.3 vs. 20.0%, p=0.004), with a significantly higher level of systolic pressure [137 (120, 160) mmHg vs. 130 (120, 140) mmHg, p=0.009]. Main laboratory findings, including serial albumin (20.4±7.8 g/L vs. 24.5±6.7 g/L, p<0.001), 24-h proteinuria [5.61 (3.10, 7.87) g/day vs. 3.82 (2.31, 5.79) g/day, p=0.002], serial creatinine [80.8 (65.8, 97.9) μmol/L vs. 72.0 (58.7, 84.9) μmol/L, p=0.003], and estimated glomerular filtration rate [86 (66, 101) mL/min/1.73 m2 vs. 95 (81, 108) mL/min/1.73 m2, p=0.007] showed significant differences between the two groups. Pathologically, patients with focal segmental glomerulosclerosis lesions appeared with a higher percentage of crescents, a more severe degree of interstitial fibrosis, and a higher level of membranous nephropathy stage. Renal phospholipase A2 receptor showed a relatively lower positive rate of only 75.0% in the FSGS+ group in comparison with the positive rate of 90.3% in the FSGS- group (p=0.031). The prognosis was generally similar between the two groups. Among patients who were given non-immunosuppression treatment, those with focal segmental glomerulosclerosis lesions took a relatively longer period of time to achieve complete remission (29.3±7.0 m vs. 15.4±8.9 m, p=0.025) and experienced a higher rate of renal function deterioration (37.5 vs. 5.4%, p=0.033) compared with the other ones. While among those receiving immunosuppression treatment, both groups received similar remission rates.
      Conclusion: Compared with FSGS- group, idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions represented more severe nephrotic syndrome and worse renal function. In view of the renal function decline during the follow-up, more aggressive treatment with the use of immunosuppressants should be considered for idiopathic membranous nephropathy patients with focal segmental glomerulosclerosis lesions.
    • References:
      BMC Nephrol. 2019 Dec 16;20(1):467. (PMID: 31842785)
      Kidney Int. 2006 May;69(9):1641-8. (PMID: 16572119)
      Pathol Res Pract. 2012 Nov 15;208(11):662-7. (PMID: 22995635)
      Perspect Nephrol Hypertens. 1973;1 Pt 1:443-8. (PMID: 4536436)
      Kidney Int. 2004 Apr;65(4):1400-7. (PMID: 15086481)
      Nephrol Dial Transplant. 2007 Aug;22(8):2201-7. (PMID: 17442739)
      Clin Nephrol. 1993 Jan;39(1):7-16. (PMID: 8428410)
      Kidney Int. 2013 May;83(5):940-8. (PMID: 23364522)
      Kidney Int. 1997 Mar;51(3):901-7. (PMID: 9067928)
      Curr Med Sci. 2022 Oct;42(5):1007-1014. (PMID: 36178577)
      Contrib Nephrol. 2013;181:22-30. (PMID: 23689564)
      BMC Nephrol. 2019 Aug 22;20(1):328. (PMID: 31438882)
      J Pathol. 1990 May;161(1):47-56. (PMID: 2370598)
      Am J Kidney Dis. 2003 Jan;41(1):38-48. (PMID: 12500220)
      N Engl J Med. 2009 Jul 2;361(1):11-21. (PMID: 19571279)
      J Am Soc Nephrol. 2014 Jun;25(6):1357-66. (PMID: 24610926)
      Kidney Int. 1992 Feb;41(2):428-34. (PMID: 1552716)
      PLoS One. 2015 Apr 15;10(4):e0116700. (PMID: 25875837)
      Acta Paediatr Jpn. 1997 Jun;39(3):349-53. (PMID: 9241899)
      Nephrol Dial Transplant. 2010 Feb;25(2):444-9. (PMID: 19808947)
      Georgian Med News. 2015 Apr;(241):49-53. (PMID: 25953939)
      Nephrol Dial Transplant. 1992;7 Suppl 1:48-52. (PMID: 1337182)
      J Nephrol. 2014 Jun;27(3):307-16. (PMID: 24523071)
      J Am Soc Nephrol. 2012 Oct;23(10):1735-43. (PMID: 22956816)
    • Accession Number:
      0 (Immunosuppressive Agents)
      0 (Receptors, Phospholipase A2)
    • Publication Date:
      Date Created: 20240508 Date Completed: 20240508 Latest Revision: 20240617
    • Publication Date:
      20250114
    • Accession Number:
      PMC11068386
    • Accession Number:
      10.1590/1806-9282.20230871
    • Accession Number:
      38716932